New drug combo aims to put the brakes on devastating ALS
NCT ID NCT07414212
Summary
This study is testing whether adding two substances, EH-301 and N-acetylcysteine (NAC), to the standard ALS drug riluzole can slow down the disease. It will involve 90 people with early-stage ALS who can still walk. Participants will be randomly assigned to get either the real combination or a placebo for six months, with the option for everyone to receive the treatment for another six months afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Donostia
RECRUITINGSan Sebastián, Guipuzcoa, 20003, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.